AtriCure, Inc.
6033 Schumacher Park Drive
West Chester
Ohio
45069
United States
Tel: 513-755-4100
Fax: 513-755-4108
Website: http://www.atricure.com/
Email: info@atricure.com
326 articles about AtriCure, Inc.
-
AtriCure to Participate at the 38th Annual JP Morgan Healthcare Conference
12/16/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming 38th Annual JP Morgan Healthcare Conference in San Francisco.
-
AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference
11/12/2019
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that the company will be participating in the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York City.
-
AtriCure Reports Third Quarter 2019 Financial Results
10/30/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2019 financial results.
-
AtriCure to Participate in Upcoming Investor Conferences
10/21/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences.
-
AtriCure to Announce Third Quarter 2019 Financial Results
10/8/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019.
-
AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices
8/27/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for AtriClip® LAA management devices, including changing the indication from occlusion of the LAA to exclusion, and also adding electrical isolation as a labeling claim
-
AtriCure to Participate at the Morgan Stanley 17th Annual Global Healthcare Conference
8/26/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17th Annual Global Healthcare Conference in New York City.
-
AtriCure Completes Acquisition of SentreHEART
8/13/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions.
-
AtriCure Enters Into Definitive Agreement to Acquire SentreHEART
8/12/2019
AtriCure, Inc. announced that it has entered into a definitive agreement to acquire SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions.
-
AtriCure Reports Second Quarter 2019 Financial Results
7/30/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2019 financial results.
-
AtriCure to Participate at the Canaccord Genuity 39th Annual Growth Conference
7/17/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Canaccord Genuity 39th Annual Growth Conference in Boston.
-
AtriCure to Announce Second Quarter 2019 Financial Results
7/10/2019
AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 30, 2019 to discuss its second quarter 2019 financial results
-
AtriCure Reports First Quarter 2019 Financial Results
4/25/2019
AtriCure, Inc., a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced first quarter 2019 financial results.
-
AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart
4/23/2019
The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation
-
AtriCure to Announce First Quarter 2019 Financial Results
4/4/2019
AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019.
-
AtriCure to Present at the Needham & Company’s 18th Annual Healthcare Conference
4/1/2019
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that it will present at the Needham & Company’s 18th Annual Healthcare Conference in New York on Wednesday, April 10, 2019.
-
AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results
2/28/2019
AtriCure, Inc., a leading innovator in treatments for atrial fibrillation (Afib) and related conditions, announced fourth quarter and full year 2018 financial results.
-
AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
2/19/2019
Endorsement complements the company’s ongoing commitment to physician education
-
AtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial
2/5/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient was treated in the ICE-AFIB™ trial (NCT03732794).
-
AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results
2/4/2019
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019.